CTOs on the Move

Bio Alberta

www.bioalberta.com

 
Bio Alberta is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Clarendale of Bellevue Place

Clarendale at Bellevue Place is a senior living community located in Nashville, TN that offers independent living, assisted living, and memory care services.

OneShare Health

OneShare Health is a medical cost-sharing ministry providing a unique, affordable, ACA-exempt path to healthcare. OneShare Health is not insurance. With origins in the Anabaptist faith and a chaplain on staff, we are a Health Care Sharing Ministry that welcomes and unites those who agree with our core biblical principles and Statement of Beliefs relating to life, health and caring for others.

Organifi

Uniting the World through Health and Happiness.

Mantra Health

Mantra Health is a digital mental health clinic on a mission to improve young peoples` mental healthcare access through clinical services, software, and design. Since our founding in 2018, we`ve built a comprehensive treatment service for young adults with various mental health conditions. We`ve raised over $27 million to work with students at universities and colleges across the country such as MIT, Cornell, and the University of Minnesota. Our students see clinically significant differences in their mental health during treatment with us. We`re particularly proud that nearly two-thirds of students with access to Mantra report that Mantra`s program helped them stay in school.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.